DiaMedica Inc.

DiaMedica Inc.

June 01, 2012 09:11 ET

DiaMedica's DM-204 Program Selected for Late Breaking Poster Presentation at the American Diabetes Association's 72nd Scientific Conference

WINNIPEG, MANITOBA--(Marketwire - June 1, 2012) - DiaMedica (TSX VENTURE:DMA) today announces that it has been selected for a Late Breaking Poster Presentation at the American Diabetes Association's 72nd Scientific Sessions, June 8-12, 2012 in Philadelphia, PA. The poster titled, "A Novel Agonist Antibody to the Bradykinin 2 Receptor for the Treatment of Type 2 Diabetes" will be presented on Sunday June 10th and covers results of pre-clinical studies of DM-204, a novel monoclonal antibody, for the treatment of Type 2 diabetes.

"The annual American Diabetes Association is a great forum for us to share the recent data generated on DM-204 as well as elaborate on its novel mechanism of action," commented Rick Pauls, Chairman and CEO of DiaMedica. "We are also using the conference as a platform to begin early stage partnering discussions with major pharmaceutical and biotechnology companies. These discussions will involve both DM-204 and DM-199, our recombinant protein for diabetes. We look forward to a series of productive meetings at the conference."

About DiaMedica

DiaMedica is a biopharmaceutical company focused on discovery and development of novel therapeutic compounds for diabetes and other major, medically-unmet diseases. DiaMedica's lead compound, DM-199, is a recombinant human protein that represents a novel approach to treating Type 1 and Type 2 diabetes. In a Type 1 diabetes model, DM-199 halted the autoimmune attack on beta cells by stimulating regulatory T-cells, and resulted in a 12-fold increase in C-peptide levels. In Type 2 diabetes models, DM-199 treatment stimulated proliferation of insulin producing beta cells, resulting in significant improvement in glucose control. DiaMedica is also developing a novel monoclonal antibody, DM-204 as a treatment for Type 2 diabetes. Chronic treatment with DM-204 in a Type 2 diabetes model resulted in significant improvement in blood glucose control and HbA1c levels and also significant decreases in blood pressure and serum cholesterol.

Diamedica's DM-199 and DM-204 were both named Windhover's "2011 Top 10 Cardiovascular/ Metabolic Projects to Watch". The Company is listed on the TSX Venture Exchange under the trading symbol 'DMA'.

Caution Regarding Forward-Looking Information The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Company's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Company undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Contact Information